Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren 2-year extension after post-myocardial infarction remodeling study
2008-001306-16Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and essential hypertension comparing Aliskiren + optimized standard therapy with Placebo + optimized standard therapy (2 arms). Primary endpoint: Long-term safety. Started Apr 2008; status: terminated.
02
Drugs
aliskiren
03
Conditions
myocardial infarction (MI)essential hypertension
Beyond the preview
Go deeper on 2008-001306-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001306-16.